Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Atkinson, Victoria"'
Autor:
Aggarwal C; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA charu.aggarwal@uphs.upenn.edu., Prawira A; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia., Antonia S; Duke Cancer Institute Center for Cancer Immunotherapy, Durham, North Carolina, USA.; Moffitt Cancer Center, Tampa, Florida, USA., Rahma O; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Tolcher A; NEXT Oncology, San Antonio, Texas, USA.; START-South Texas, San Antonio, Texas, USA., Cohen RB; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Lou Y; Mayo Clinic, Jacksonville, Florida, USA., Hauke R; Nebraska Cancer Specialists, Omaha, Nebraska, USA., Vogelzang N; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA., P Zandberg D; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA., Kalebasty AR; Norton Cancer Institute, Louisville, Kentucky, USA., Atkinson V; Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Adjei AA; Mayo Clinic, Rochester, Minnesota, USA., Seetharam M; Mayo Clinic, Scottsdale, Arizona, USA., Birnbaum A; Rhode Island Hospital, Providence, Rhode Island, USA., Weickhardt A; Austin Health, Heidelberg, Victoria, Australia., Ganju V; Peninsula and Southeast Oncology, Frankston, Victoria, Australia., Joshua AM; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia., Cavallo R; MacroGenics, Inc, Rockville, Maryland, USA., Peng L; MacroGenics, Inc, Rockville, Maryland, USA., Zhang X; MacroGenics, Inc, Rockville, Maryland, USA., Kaul S; AstraZeneca, Gaithersburg, Maryland, USA., Baughman J; MacroGenics, Inc, Rockville, Maryland, USA., Bonvini E; MacroGenics, Inc, Rockville, Maryland, USA., Moore PA; MacroGenics, Inc, Rockville, Maryland, USA., Goldberg SM; MacroGenics, Inc, Rockville, Maryland, USA., Arnaldez FI; MacroGenics, Inc, Rockville, Maryland, USA.; AstraZeneca, Gaithersburg, Maryland, USA., Ferris RL; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Lakhani NJ; START Midwest, Grand Rapids, Michigan, USA.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Apr; Vol. 10 (4).
Autor:
Atkinson V; Division of Cancer Services, University of Queensland, Princess Alexandra Hospital Clinical School, Woolloongabba, Queensland, Australia.; Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia., Khattak A; Department of Medical Oncology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.; Medical Oncology, Edith Cowan University, Joondalup, Western Australia, Australia., Haydon A; Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia., Eastgate M; Medical Oncology Clinical Trials Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia., Roy A; Oncology Research, Flinders Medical Centre, Bedford Park, South Australia, Australia., Prithviraj P; Ballarat Health Services, Ballarat Base Hospital, Ballarat, Victoria, Australia., Mueller C; Clinical Development, Immutep GmbH, Berlin, Germany., Brignone C; Research and Development, Immutep SAS, Orsay, France., Triebel F; Research and Development, Immutep SAS, Orsay, France ftriebel@immutep.com.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Nov; Vol. 8 (2).
Autor:
Eggermont AMM; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. Electronic address: alexander.eggermont@gustaveroussy.fr., Blank CU; Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Mandala M; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy., Long GV; Melanoma Institute Australia, The University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, NSW, Australia., Atkinson VG; Princess Alexandra Hospital, Brisbane, QLD, Australia., Dalle S; Hospices Civils de Lyon Cancer Institute, Lyon, France., Haydon A; Alfred Hospital, Melbourne, VIC, Australia., Lichinitser M; Russian Oncology Scientific Centre, Moscow, Russia., Khattak A; Fiona Stanley Hospital/University of Western Australia, Perth, WA, Australia., Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia., Sandhu S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Larkin J; Royal Marsden Hospital, London, United Kingdom., Puig S; Hospital Clinic Universitari de Barcelona, Barcelona, Spain., Ascierto PA; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Rutkowski P; Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland., Schadendorf D; Universitaetsklinikum - University Essen, Essen, Germany., Koornstra R; Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands., Hernandez-Aya L; Washington University School of Medicine, St. Louis, MO, USA., Di Giacomo AM; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy., van den Eertwegh AJ; Amsterdam University Medical Center, Location VUMC, Amsterdam, the Netherlands., Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France., Gutzmer R; Skin Cancer Center, Hannover Medical School, Hannover, Germany., Jamal R; Centre Hospitalier de l'Université de Montréal (CHUM), Centre de recherche du CHUM, Montreal, QC, Canada., Lorigan PC; Christie NHS Foundation Trust, Manchester, United Kingdom., Lupinacci R; Merck & Co., Inc., Kenilworth, NJ, United States., Krepler C; Merck & Co., Inc., Kenilworth, NJ, United States., Ibrahim N; Merck & Co., Inc., Kenilworth, NJ, United States., Kicinski M; EORTC Headquarters, Brussels, Belgium., Marreaud S; EORTC Headquarters, Brussels, Belgium., van Akkooi AC; Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Suciu S; EORTC Headquarters, Brussels, Belgium., Robert C; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Jul; Vol. 116, pp. 148-157. Date of Electronic Publication: 2019 Jun 11.
Autor:
Xu W; Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba.; The University of Queensland, Brisbane., Moor RJ; Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba., Walpole ET; Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba.; The University of Queensland, Brisbane., Atkinson VG; Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba.; The University of Queensland, Brisbane.; Greenslopes Private Hospital, Cyril Gilbert Cancer Centre, Greenslopes, Queensland, Australia.
Publikováno v:
Melanoma research [Melanoma Res] 2019 Jun; Vol. 29 (3), pp. 333-337.
Autor:
Ascierto PA; Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy., Long GV; Melanoma Institute Australia, Sydney, New South Wales, Australia.; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Robert C; Department of Medicine, Institute Gustave Roussy, Villejuif, France., Brady B; Medical Oncology and Haematology, Cabrini Health, Melbourne, Victoria, Australia., Dutriaux C; Dermatology Service, University Hospital of Bordeaux, Bordeaux, France., Di Giacomo AM; UOC Oncological Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy., Mortier L; Clinique de Dermatologie, Unité d'Onco-Dermatologie, Institut National de la Santé et de la Recherche Médicale (INSERM) U1189, Centre Hospitalier Régional Universitaire de Lille, Lille, France., Hassel JC; Department of Dermatology, University Hospital Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany., Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland., McNeil C; Chris O'Brien Lifehouse, Melanoma Institute Australia, Camperdown, New South Wales.; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Kalinka-Warzocha E; Polish Mother's Memorial Hospital Research Institute, Lodz, Poland., Savage KJ; Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada., Hernberg MM; Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland., Lebbé C; Assistance Publique-Hôpitaux de Paris Dermatology and Centre d'Investigation Clinique, University Paris Diderot INSERM U976, Saint Louis Hospital, Paris, France., Charles J; Institute for Advanced Biosciences, Université Grenoble Alpes/INSERM U1209/CNRS UMR 5309 Joint Research Center, Grenoble, France.; Dermatology Department, Grenoble Alpes University Hospital, Grenoble, France., Mihalcioiu C; Department of Oncology, McGill University, Montreal, Quebec, Canada., Chiarion-Sileni V; Melanoma Cancer Unit, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy., Mauch C; Department of Dermatology, University Hospital Cologne, Cologne, Germany., Cognetti F; Division of Oncology, Regina Elena Institute, Rome, Italy., Ny L; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden., Arance A; Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain., Svane IM; Center for Cancer Immune Therapy, Herlev Hospital, Herlev, Denmark.; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany.; German Cancer Consortium, Heidelberg, Germany., Gogas H; First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Saci A; Global Biometric Sciences, Bristol-Myers Squibb, Princeton, New Jersey., Jiang J; Global Biometric Sciences, Bristol-Myers Squibb, Princeton, New Jersey., Rizzo J; Oncology Clinical Development, Bristol-Myers Squibb, Princeton, New Jersey., Atkinson V; Princess Alexandra Hospital, University of Queensland, Woolloongabba, Queensland, Australia.; Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
Publikováno v:
JAMA oncology [JAMA Oncol] 2019 Feb 01; Vol. 5 (2), pp. 187-194.
Autor:
Tio M; Melanoma Institute Australia, Sydney, Australia. Electronic address: mtio0565@uni.sydney.edu.au., Rai R; Melanoma Institute Australia, Sydney, Australia., Ezeoke OM; Memorial Sloan Kettering Cancer Center, New York, USA., McQuade JL; MD Anderson Cancer Center, Houston, USA., Zimmer L; University of Duisburg-Essen Hospital, Heidelberg, Germany., Khoo C; Peter MacCallum Cancer Centre, Melbourne, Australia., Park JJ; Crown Princess Mary Cancer Centre, Sydney, Australia; Westmead Hospital, Sydney, Australia., Spain L; Skin and Renal Unit, The Royal Marsden NHS Foundation Trust, London, UK., Turajlic S; Skin and Renal Unit, The Royal Marsden NHS Foundation Trust, London, UK; Francis Crick Institute, London, UK., Ardolino L; St Vincents Hospital, Sydney, Australia., Yip D; The Canberra Hospital, Canberra, Australia; ANU Medical School, Australian National University, Canberra, Australia., Goldinger SM; University Hospital Zurich, Zurich, Switzerland., Cohen JV; Massachusetts General Hospital, Boston, USA., Millward M; Sir Charles Gairdner Hospital, Perth, Australia., Atkinson V; Princess Alexandra Hospital, Brisbane, Australia., Kane AY; Liverpool Hospital, Sydney, Australia; Garvan Institute, Sydney, Australia., Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy., Garbe C; University of Tubingen, Tubingen, Germany., Gutzmer R; Hannover Medical School, Hannover, Germany., Johnson DB; Vanderbilt Ingram Cancer Center, Nashville, USA., Rizvi HA; Memorial Sloan Kettering Cancer Center, New York, USA., Joshua AM; Melanoma Institute Australia, Sydney, Australia; St Vincents Hospital, Sydney, Australia; University of New South Wales, Sydney, Australia., Hellmann MD; Memorial Sloan Kettering Cancer Center, New York, USA., Long GV; Melanoma Institute Australia, Sydney, Australia; The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia., Menzies AM; Melanoma Institute Australia, Sydney, Australia; The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2018 Nov; Vol. 104, pp. 137-144. Date of Electronic Publication: 2018 Oct 20.
Autor:
Long GV; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au., Atkinson V; Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia., Lo S; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Sandhu S; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia., Guminski AD; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Brown MP; Royal Adelaide Hospital, Centre for Cancer Biology (SA Pathology and University of South Australia) and University of Adelaide, Adelaide, SA, Australia., Wilmott JS; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Edwards J; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Gonzalez M; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia., Menzies AM; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., McArthur GA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; Medical, Dental and Health Sciences, University of Melbourne, Parkville, VIC, Australia.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2018 May; Vol. 19 (5), pp. 672-681. Date of Electronic Publication: 2018 Mar 27.
Autor:
Long GV; Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, North Sydney, New South Wales, Australia., Weber JS; Department of Medical Oncology, Moffitt Cancer Center, Tampa, Florida.; now with Department of Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York., Larkin J; Department of Oncology, Royal Marsden Hospital, London, United Kingdom., Atkinson V; Gallipoli Medical Research Foundation and Princess Alexandra Hospital, and University of Queensland, Queensland, Australia., Grob JJ; Department of Dermatology and Skin Cancer, Hospital Timone APHM, Aix-Marseille University, Marseille, France., Schadendorf D; Department of Skin, University Hospital Essen, Essen, Germany.; Department of Urology, University Hospital Essen, Essen, Germany., Dummer R; Department of Dermatology, UniversitaetsSpital, Zurich, Switzerland., Robert C; Department of Medicine Institute Gustave Roussy, Gustave Roussy and Paris-Sud University, Villejuif Paris-Sud, France., Márquez-Rodas I; Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain., McNeil C; Chris O'Brien Lifehouse, Melanoma Institute Australia, Camperdown, New South Wales, Australia.; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Schmidt H; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Briscoe K; Department of Medical Oncology, Coffs Harbour Health Campus, New South Wales, Australia., Baurain JF; Melanoma Clinic at King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium., Hodi FS; Melanoma Center and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wolchok JD; Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, New York.
Publikováno v:
JAMA oncology [JAMA Oncol] 2017 Nov 01; Vol. 3 (11), pp. 1511-1519.
Autor:
Ladwa R; aDepartment of Medical Oncology, Princess Alexandra Hospital bDepartment of Medical Oncology, Greenslopes Private Hospital cSchool of Medicine, University of Queensland, Brisbane, Queensland, Australia., Atkinson V
Publikováno v:
Melanoma research [Melanoma Res] 2017 Apr; Vol. 27 (2), pp. 168-170.
Autor:
Grant A. McArthur, Michael P. Brown, Shahneen Sandhu, Jarem Edwards, James S. Wilmott, Victoria Atkinson, Alexander M. Menzies, Alexander Guminski, Serigne Lo, Georgina V. Long, María Jesús González González, Richard A. Scolyer
Publikováno v:
The Lancet. Oncology. 19(5)
Summary Background Nivolumab monotherapy and combination nivolumab plus ipilimumab increase proportions of patients achieving a response and survival versus ipilimumab in patients with metastatic melanoma; however, efficacy in active brain metastases